NMRA 10-Q: SEC filing
Neumora Therapeutics
Filed with the SEC on · accession 0001193125-26-462194
NMRA filed a 10-Q (quarterly report) with the SEC on Nov 16, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -13.8% by the first close after the filing.
Summary of the filing
Neumora Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results including cash position, R&D and G&A expenses, and details of its license agreements and loan facilities.
Key details
How NMRA stock reacted
Close before
$0.43
Nov 13, 2026
First close after
-13.85%
$0.37
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for NMRA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for NMRA?
Click hereFrequently asked questions
What did NMRA file with the SEC on Nov 16, 2026?
NMRA filed a 10-Q (SEC filing). Neumora Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results including cash position, R&D and G&A expenses, and details of its license agreements and loan facilities.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did NMRA stock react to this filing?
NMRA closed at $0.43 before the filing and $0.37 on Nov 16, 2026 (-13.85%).
Other NMRA SEC filings
- SCHEDULE 13G/A · SEC filingNov 16, 2026
- 8-K · SEC filingNov 16, 2026
- 8-K · Delisting noticeOct 30, 2026
- 10-Q · SEC filingAug 14, 2026
- 8-K · Ceo changeAug 14, 2026
- 8-K · Fda approvalJul 27, 2026
- 8-K · Fda rejectionJun 15, 2026
- 8-K · Board changeMay 29, 2026
- 10-Q · SEC filingMay 7, 2026
- 8-K · SEC filingMay 7, 2026
Get alerts when NMRA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days